Toralizumab
Product Specifications
UNSPSC Description
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research[1][2].
Target Antigen
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/toralizumab.html
Purity
99.57
Solubility
H2O
Smiles
[Toralizumab]
References & Citations
[1]Camilo E Fadul, et al. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 15;8(6):e1096.|[2]Kenneth C Kalunian, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec;46(12):3251-8.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99325/Toralizumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99325/Toralizumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
252662-47-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
